Background: The aim of this paper is to present our experience concerning cooperation in the treatment of Slovak patients with differentiated thyroid cancer in Slovak and Czech hospitals. The objectives of this study were to demonstrate the means of this cooperation and the results of therapy.
Material And Methods: From September 1991 to October 2005 in the Department of Nuclear Medicine in Ostrava 357 patients from the Slovak Republic with differentiated thyroid cancers (follicular and papillary) underwent complex therapy. They were diagnosed and operated due to the cancer (near-total thyroidectomy and removal of lymph node metastases) in Slovak hospitals. Then they were sent to the Department of Nuclear Medicine in Ostrava in the Czech Republic. In this department a radioiodine ablation of thyroid remnants, by means of the treatment amount of radioiodine of a standard activity of 3.7 GBq, was performed, and then a suppression and substitution therapy of thyroid hormones was started. After 3-6 months some patients were examined by means of diagnostic whole body scintigraphy after application of 300 MBq 131I. Some patients were treated by means of a standard activity of 7.4 GBq 131I and after 5 days whole body scintigraphy (WBS) was performed. In both of these groups of patients the diagnostic or therapeutic radioiodine application was done after withdrawal of thyroid hormone treatment. If thyroglobulin levels were low and WBSs were negative, patients were followed up in the Department of Nuclear Medicine in Martin. Patients with radioiodine accumulated metastases were again treated with radioiodine in Ostrava. If indicated, external radiation therapy targeted on the neck and upper mediastinum was performed in the Slovak Republic, in the University Hospital in Martin. Newly formed lymph node metastases were surgically treated in Slovakia, too. Generally we have very good treatment results. Also, economically our partnership is cost effective. Our collaboration also successfully continues after entrance of the Slovak Republic and the Czech Republic to the European Union in 2004.
Conclusions: The results of this multi-centre study show that international Czech and Slovak cooperation in the complex therapy of patients with differentiated thyroid cancers is successful, with high efficacy. The treatment results were very similar to therapeutic results in our patients from the Czech Republic.
Download full-text PDF |
Source |
---|
Discov Med
January 2025
Breast Surgery, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, 250001 Jinan, Shandong, China.
Background: Zinc finger proteins (ZNFs) have been proved to play important roles in driving the progression of breast cancer (BC), one of the most common cancers among women. This study aimed to investigate the involvement of zinc-finger SWIM domain-containing protein 3 () in promoting BC cell progression by regulating lipid metabolism.
Methods: Differential expression of in BC was confirmed by comparing its expression in normal human mammary epithelial cells and BC cells.
PeerJ
January 2025
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), i3S-Institute for Research & Innovation in Health, Porto, Portugal.
Background: The differential diagnosis between benign and malignant thyroid nodules continues to be a major challenge in clinical practice. The rising incidence of thyroid neoplasm and the low incidence of aggressive thyroid carcinoma, urges the exploration of strategies to improve the diagnostic accuracy in a pre-surgical phase, particularly for indeterminate nodules, and to prevent unnecessary surgeries. Only in 2022, the 5th WHO Classification of Endocrine and Neuroendocrine Tumors, and in 2023, the 3rd Bethesda System for Reporting Thyroid Cytopathology and the European Thyroid Association included biomarkers in their guidelines.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Platelet-derived growth factor alpha (PDGFRA) plays a significant role in various malignant tumors. PDGFRA expression boosts thyroid cancer cell proliferation and metastasis. Radiorefractory thyroid cancer is poorly differentiated, very aggressive, and resistant to radioiodine therapy.
View Article and Find Full Text PDFVirchows Arch
January 2025
Department of Oncology, University of Turin, Orbassano, Turin, Italy.
In non-papillary follicular cell-derived thyroid carcinomas, prognostic factors are scarce. Intratumoral fibrosis was identified as an adverse factor in papillary and medullary carcinomas, but it has not been investigated in other subtypes. We aimed at exploring the presence of intratumoral fibrosclerosis in a cohort of 132 non-papillary follicular cell-derived thyroid carcinomas (53 follicular and 31 oncocytic carcinomas, including 10 high grade differentiated thyroid carcinomas and 48 poorly differentiated carcinomas) and correlating its presence and extent with clinical and pathological features and survival.
View Article and Find Full Text PDFFree Radic Biol Med
January 2025
Department of Environmental Health, College of Preventive Medicine, Third Military Medical University, Chongqing, 400038, China; Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing, 400038, China. Electronic address:
Bisphenol F (BPF) has become a new risk factor for male semen quality, but its specific mechanism is still unclear. Therefore, this study explored the potential mechanism of BPF affecting male semen quality from the perspective of ferroptosis and m6A RNA methylation. In vivo experiments showed that BPF destroyed the structure of seminiferous tubules, reduced the layers of spermatogenic cells, and reduced semen quality in mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!